Peptide-receptor radionuclide therapy for endocrine tumors

[1]  J. Hoppin,et al.  Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats , 2008, Nuklearmedizin.

[2]  F. Ashoori,et al.  Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.

[3]  F. Forrer,et al.  Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Schulz,et al.  Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Krenning,et al.  Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  E. Krenning,et al.  Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  F. Forrer,et al.  Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[9]  Richard P Baum,et al.  Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. , 2007, Cancer biotherapy & radiopharmaceuticals.

[10]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[11]  R. Valkema,et al.  Peptide receptor scintigraphy (PRS) with In-111-DOTANOC and peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTANOC , 2007 .

[12]  E. Krenning,et al.  Targeted radiotherapy of neuroendocrine tumors using Lu-177-DOTA octreotate with prolonged intervals , 2007 .

[13]  F. Forrer,et al.  Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  F. Keleştimur,et al.  Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[15]  E. Krenning,et al.  Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[17]  Eva Forssell-Aronsson,et al.  Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. , 2006, Nuclear medicine and biology.

[18]  E. Krenning,et al.  Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  E. P. Krenning,et al.  Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  J. Paulus,et al.  Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors , 2006, Digestive Diseases and Sciences.

[21]  Raffaella Barone,et al.  Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[22]  A. Sasse,et al.  Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. , 2006, International journal of radiation oncology, biology, physics.

[23]  E. Krenning,et al.  Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs , 2006, Trends in Endocrinology & Metabolism.

[24]  B. Bernard,et al.  Anticancer activity of targeted proapoptotic peptides. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  F. Forrer,et al.  Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  B. Bernard,et al.  111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  E. Krenning,et al.  Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  E. Krenning,et al.  Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  P. Ruszniewski,et al.  Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours , 2004, Neuroendocrinology.

[32]  B. Bernard,et al.  Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  R. Baum,et al.  Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren , 2004, Der Onkologe.

[34]  B. Bernard,et al.  Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. , 2004, Cancer biotherapy & radiopharmaceuticals.

[35]  J. Smit,et al.  Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study , 2004, Nuclear medicine communications.

[36]  E. Krenning,et al.  Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Rich,et al.  Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Paul J Yazaki,et al.  A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  B. Bernard,et al.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  B. Bernard,et al.  Anti‐tumor effect and increased survival after treatment with [177Lu‐DOTA0,Tyr3]octreotate in a rat liver micrometastases model , 2003, International journal of cancer.

[41]  E. P. Krenning,et al.  Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  J. Buscombe,et al.  Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  A. Hinke,et al.  Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  M. Cremonesi,et al.  Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group , 2002 .

[47]  R. Moncayo,et al.  111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial , 2002 .

[48]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.

[49]  E. Woltering,et al.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. , 2002, Seminars in nuclear medicine.

[50]  L. Kvols,et al.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. , 2002, Seminars in nuclear medicine.

[51]  C. Grana,et al.  90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. , 2002, Biopolymers.

[52]  R. Moncayo,et al.  Results and Implications of the MAURITIUS Trial , 2002 .

[53]  R. Moncayo,et al.  In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. , 2002, Seminars in nuclear medicine.

[54]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[56]  C. Waldherr,et al.  The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  B. Bernard,et al.  [177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy , 2001, International journal of cancer.

[58]  O. Visser,et al.  Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  J. Laissue,et al.  Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.

[60]  R. Jian,et al.  The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors , 2000, American Journal of Gastroenterology.

[61]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[62]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[63]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[64]  L. Holmberg,et al.  Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[66]  K. Oberg,et al.  Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. , 1993, Acta oncologica.

[67]  R. Arnold,et al.  Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour Growth , 1993 .